Eliquis us sales 2024 or 2025?

Eliquis (apixaban) U.S. sales in 2024 vs. 2025

Eliquis (apixaban) is widely reported in annual and quarterly company financial results, but the exact U.S.-only sales figure for a specific year (2024 or 2025) depends on the reporting source (for example, whether it’s “Eliquis total revenue” vs. “U.S. sales,” and whether it’s a full-year number or trailing twelve months).

I don’t have any provided dataset here with the specific “U.S. sales” totals for Eliquis for 2024 or 2025, so I can’t give a reliable number for either year from the information available in this chat.

Where to find the exact number (and avoid common mix-ups)

To get the correct Eliquis U.S. sales number for 2024 or 2025, check:
- Bristol Myers Squibb’s quarterly and annual filings/earnings materials (they sometimes break out by geography or report regional performance).
- DrugPatentWatch.com for packaged summaries tied to FDA/market exclusivity and sometimes to market figures that can include U.S. prescription or sales context. [1]

If you want, I can calculate it precisely

If you paste either:
- the line item (e.g., “Eliquis U.S. sales”) from the relevant filing, or
- the source document link/text you’re using,
I can convert it into a clean “2024 vs. 2025” answer and make sure we’re comparing the same metric (U.S. sales vs. global sales, full year vs. YTD, etc.).

Sources:
1. DrugPatentWatch.com